You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

  • Technology appraisal guidance
  • Reference number: TA238
  • Published:  14 December 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Arthritis (juvenile idiopathic, systemic) - tocilizumab: consultee and commentator comments on the ACD

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Roche comments on ACD

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Roche comments on ACD - PAS template

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Roche comments on ACD - PSA

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Roche comments on ACD - additional analysis as requested by ERG

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Roche comments on ACD - erratum PSA for PAS

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: NRAS comments on ACD

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: BSPAR comments on ACD

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: Abbott comments on ACD

  • Arthritis (juvenile idiopathic, systemic) - tocilizumab: ARUK comments on ACD


This page was last updated: 26 October 2011

Back to top